Metadata
- Name
- Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT04100694
- Description
- Merus is providing single patient/named access to the HER2/HER3 bispecific antibody,
MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access
program who are ineligible for an ongoing MCLA-128 clinical trial or have other
considerations that prevent access to MCLA-128 through an existing clinical trial.
Participating sites will be added as they apply for and are approved for the EAP. A medical
doctor must decide whether the potential benefit outweighs the risk of receiving an
investigational therapy based on the individual's medical history and program eligibility
criteria. - Data or Study Types
- clinical trial
- Keywords
- Compassionate use, Solid tumor, Pancreas cancer, Non Small Cell Lung Cancer, Expanded access, NRG1, Early Access
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2019
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT04100694
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04100694